Abstract 1536P
Background
HER-Vaxx is a B cell peptide-based anti-Her2 vaccine (IMU-131) comprising B cell epitopes located within trastuzumab’s binding site. In the phase Ib HERIZON trial (NCT02795988), HER-Vaxx has been shown to be safe and to prolong progression-free survival in patients with Her2-overexpressing gastric/gastro-oesophageal junction cancer (GC). The present randomized phase II open-label, multicentre study, compared two different doses of HER-Vaxx plus chemotherapy vs chemotherapy alone and aimed to evaluate antibody and clinical responses in patients with advanced or metastatic Her2-overexpressing GC naïve to Her2 therapy.
Methods
Patients were randomized to chemotherapy alone (n=17) or HER-Vaxx (50μg dose, n=19; 100μg, n=7) plus chemotherapy. In both vaccination groups, the patients received the vaccine at days 0, 14, 35, and 77 followed by q. 63 days until disease progression. Chemotherapy consisted of oxaliplatin plus capecitabine and was started at day 0, repeated q. 21 days for a maximum of 6 cycles. Specific anti-Her2 IgG antibody levels in the patient’s sera were evaluated by ELISA and clinical responses were assessed by RECIST 1.1 criteria.
Results
Evaluation of the vaccine’s two doses showed no difference in the induced Her2-specific IgG and IgG1 antibody responses, which, compared to patients from the chemotherapy-only group, were both significantly elevated (P<0.001) at all time points after 3 or more vaccinations. No further reduction of tumour diameters was observed with the vaccine’s higher dose, and the induced Her2-specific antibodies following vaccination with either dose significantly correlated with the anti-tumour effect (IgG, P=0.001; IgG1, P=0.016). Moreover, the vaccine-induced IgG antibodies had the capacity to inhibit intracellular phosphorylation of Her2 and exhibited binding to the gastric cancer cell line N87 overexpressing Her2.
Conclusions
Vaccination with HER-Vaxx in patients with Her2-overexpressing GC at doses of 50μg and 100μg led to an anti-tumour effect that correlated with anti-Her2 IgG antibody levels.
Clinical trial identification
NCT02795988.
Editorial acknowledgement
Legal entity responsible for the study
Imugene Limited.
Funding
Has not received any funding.
Disclosure
C. Zielinski: Other, Personal, Other, Consultancies and Speaker’s Honoraria: Athenex, MSD, AstraZeneca, Servier, Eli Lilly; Other, Personal, Other, Patents: Imugene Limited; Other, Institutional, Other: BMS, MSD, Pfizer, AstraZeneca, Merck KgAa, Amgen, Servier, Eli Lilly, Takeda, Daiichi Sankyo, Roche, Boehringer Ingelheim, Celgene, Halozyme. L.O. Chong: Financial Interests, Personal, Leadership Role: Imugene Limited. B. Nixon: Financial Interests, Personal, Stocks/Shares: Imugene Limited; Financial Interests, Personal, Full or part-time Employment: Imugene Limited; Financial Interests, Personal, Other, Spouse/Financial dependent: Imugene Limited. S. Yavrom, N. Ede: Financial Interests, Personal, Full or part-time Employment: Imugene Limited. U. Wiedermann: Other, Personal, Other, CSO of Imugene until September 2018; Patents: Imugene Limited; Other, Institutional, Other, Funding to the Institute: GSK, Pfizer, Themis. All other authors have declared no conflicts of interest.
Resources from the same session
1508TiP - The 1920-EORTC-BIORADON study: Molecular characterization of non-small cell lung cancer (NSCLC) and indoor radon exposure in Europe
Presenter: Laura Mezquita
Session: Poster session 21
1509TiP - The 1825-EORTC, ALKALINE: Activity of lorlatinib based on ALK resistance mutations on blood in ALK positive NSCLC patients previously treated with second generation ALK inhibitor
Presenter: Laura Mezquita
Session: Poster session 21
1510TiP - Efficacy study of osimertinib in treatment-naïve patients with EGFR mutant non-small cell lung cancer (NSCLC) according to TP53 mutational status (TEMPLE-2/NCT05785208)
Presenter: Antonio Vitale
Session: Poster session 21
1515P - Maintenance rucaparib after first-line platinum-based chemotherapy in advanced esophagogastric (OG) adenocarcinoma: Interim results from the PLATFORM trial
Presenter: Anderley Gordon
Session: Poster session 21
1518P - Zanidatamab (zani) plus chemotherapy (chemo) and tislelizumab (tis) as first-line (1l) therapy for patients (pts) with advanced HER2-positive (+) gastric/gastroesophageal junction adenocarcinoma (GC/GEJC): Updated results from a phase Ib/II study
Presenter: Keun-Wook Lee
Session: Poster session 21
1520P - Perioperative treatment in resectable gastric cancer with spartalizumab combined with fluorouracil, leucovorin, oxaliplatin, and docetaxel (FLOT): The GASPAR phase II trial
Presenter: Melanie Dos Santos
Session: Poster session 21